Latest EW news

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

MarketBeat · Thu, 17 Sep 2026 07:02:27 -0400

Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Seeking Alpha · Wed, 16 Sep 2026 13:01:38 -0400

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Edwards Lifesciences Comments on TAVR National Coverage Decision

Business Wire · Thu, 10 Sep 2026 17:49:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.

Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · Mon, 07 Sep 2026 15:32:00 -0400

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

Business Wire · Wed, 02 Sep 2026 16:15:00 -0400

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

Zacks Investment Research · Thu, 20 Aug 2026 11:46:05 -0400

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Zacks Investment Research · Fri, 14 Aug 2026 12:41:13 -0400

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Market information is provided for research and visualization and is not investment advice.